ストックスクリーナーアプリを入手
0.82
10.83%
0.0801
アフターアワーズ：
.82
Longeveron Inc (LGVN) 最新ニュース
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
Longeveron Stock Price Forecast. Should You Buy LGVN? - StockInvest.us
Longeveron Inc. (LGVN) investors disclose 9% beneficial stake through warrant holdings - Stock Titan
Longeveron LLC earnings missed by $0.01, revenue fell short of estimates - Investing.com Nigeria
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update - BioSpace
Longeveron Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Longeveron Q2 Results: Net loss rises 22% to $6.1 million - scanx.trade
LGVN: Q2 2026 net loss rose to $6.1M as HLHS trial data and XPRIZE finalist status drive near-term focus - TradingView
Earnings call transcript: Longeveron misses Q2 2026 estimates as cash runs tight - Investing.com
Longeveron Inc. (LGVN) Q2 FY2026 earnings call transcript - Yahoo Finance
Longeveron Reports $6.1 Million Q2 Net Loss Ahead Of ELPIS II Data - Quiver Quantitative
Longeveron Q2 net loss widens on higher legal, clinical trial costs - TradingView
LGVN: Q2 2026 net loss rose 22% as clinical and legal expenses increased ahead of key trial results - TradingView
Longeveron Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings To Watch: Longeveron Inc (LGVN) Q2 2026 -- GF Value Sees 58% Downside - Yahoo Finance
Longeveron Selected as XPRIZE Healthspan Milestone 2 Awardee for Laromestrocel Clinical Trial Results - Quiver Quantitative
Longeveron Named a Finalist Team and Will Receive a - GlobeNewswire
Longeveron Inc. (LGVN): Millennium group discloses 5.2% Class A equity stake - Stock Titan
Longeveron Restores Nasdaq Compliance with New Audit Committee - TipRanks
Earnings Preview: Longeveron to Report Financial Results Post-market on August 12 - Moomoo
LGVN Q2'26 Earnings: revenue estimate is 326.00K USD - TradingView
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming DeadlineLGVN - TMX Newsfile
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 - manilatimes.net
Longeveron will share second-quarter results after markets close Aug. 12 - Stock Titan
Longeveron (LGVN) Surges 13.45% to $0.68: Clinical-Stage Biotech Tests Key ResistanceAdvance Decline Volume - dars.gov.et
Longeveron Inc. Announces Reconstitution of Audit Committee - marketscreener.com
Longeveron Inc. Revenue Breakdown – NASDAQ:LGVN - tradingview.com
Longeveron Inc (LGVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Longeveron Inc (LGVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Longeveron Inc (LGVN) Cash Flow - TradingKey
Longeveron Inc (LGVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LGVN|Longeveron Inc|Price:0.600|Chg%:-0.007 - TradingKey
Longeveron Inc (LGVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Longeveron Inc (LGVN) Institutional Confidence - TradingKey
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
TradingKey - TradingKey
Longeveron Inc (LGVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors - BioSpace
Longeveron Inc. Elects Deborah D. Ascheim, M.D., to Board of Directors - Quiver Quantitative
Longeveron : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
$Longeveron (LGVN.US)$ - moomoo.com
Longeveron Enhances CEO Compensation and Retention Protections - TipRanks
Can Upcoming HLHS Trial Data Drive A Valuation Re-Rating For Longeveron? - RTTNews
Longeveron Inc. (LGVN) Q1 2026 Earnings: EPS Misses Estimates, Stock Declines 3.45%New Analyst Coverage - dars.gov.et
Longeveron Inc. Signs Revised CEO Employment Agreement – Key Details from July 2026 Form 8-K Filing - Minichart
Longeveron Inc. (LGVN) director files Form 3 showing no share holdings - Stock Titan
Longeveron (NASDAQ: LGVN) updates CEO severance and equity vesting - Stock Titan
Longeveron Inc. (LGVN) director Leah Cann reports no stock ownership - Stock Titan
Longeveron Presents AAIC Data Showing Laromestrocel Stabilizes Brain Inflammation in Alzheimer’s Disease - Quiver Quantitative
Stem cell therapy laromestrocel links brain scan changes to better cognition in Alzheimer’s trial - Stock Titan
Longeveron therapy reduces neuroinflammation in Alzheimer’s patients - scanx.trade
Longeveron (LGVN) Sees Modest Uptick as Stock Nears $0.69 ResistanceChandelier Stop - dars.gov.et
Longeveron Inc. Issues Special Equity Awards to Executive Chairman – SEC 8-K Filing Highlights Company Growth 7 - Minichart
Form 4 Longeveron LLC For: 8 July By Investing.com - Investing.com Nigeria
Longeveron (LGVN) CSO Hare granted 600k RSUs and 400k options - Stock Titan
Longeveron grants special equity awards to Executive Chairman - TipRanks
Longeveron (LGVN) awards 600,000 RSUs and 400,000 options to Executive Chairman - Stock Titan
Longeveron strengthens financial leadership with new CFO appointment - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Longeveron names Marie Washburn as CFO - MSN
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):